^
Association details:
| Biomarker: | MSH3 overexpression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | ifosfamide (Bifunctional alkylating agent) + epirubicin (Topoisomerase II inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Prognostic role of MRP1 in localized high-risk soft tissue sarcoma (STS): Translational research associated to randomized phase III trial (ISG-STS 1001).
Published date:
05/13/2020
Excerpt:
MRP1 overexpression was related to significant worse prognosis in 2 prospective randomized series of high-risk, localized, STS treated with neoadjuvant epirubicin and ifosfamide.
DOI:
10.1200/JCO.2020.38.15_suppl.11543
Trial ID:
